Oxford Biomedica PLC Director Shareholding (8646W)

TIDMOXB

RNS Number : 8646W

Oxford Biomedica PLC

29 April 2016

Oxford BioMedica plc Director's Share Purchase

Oxford, UK - 29 April 2016: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed that on 29 April 2016 one of its Directors acquired ordinary shares of 1p each ("Ordinary Shares") as follows:

 
                                                        Interest after 
                                                         purchase 
------------  ----------  ----------  ----------------  ---------------------------- 
  Director      Title       Price        Number of         Number       % of total 
   / PDMR                  per share   Ordinary Shares   of Ordinary      issued 
                              (p)         acquired         Shares      share capital 
------------  ----------  ----------  ----------------  ------------  -------------- 
              Executive 
Peter Nolan    director    5.5567p        359,925        1,401,968        0.05% 
------------  ----------  ----------  ----------------  ------------  -------------- 
 

The issued share capital of the Group is 2,702,901,494 1p ordinary shares.

- Ends -

 
 For further information, please 
  contact: 
  Oxford BioMedica plc:                    Tel: [phone] 
   John Dawson, Chief Executive Officer     783 000 
   Tim Watts, Chief Financial Officer 
  Consilium Strategic Communications       Tel: +44 (0)20 
   Mary-Jane Elliott/Matthew Neal/Chris     3709 5700 
   Welsh/Laura Thornton 
 

Notes for editors

About Oxford BioMedica(R)

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica has built a sector leading lentiviral vector delivery platform (LentiVector(R) ) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 230 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHUKOURNOASUAR

(END) Dow Jones Newswires

April 29, 2016 08:35 ET (12:35 GMT)